Changes of serum uric acid levels in patients with chronic hepatitis C after using direct antiviral agents therapy.
10.3760/cma.j.cn501113-20200909-00508
- Author:
Jing LIANG
1
;
Fang LIU
2
;
Ya Ping ZHANG
3
;
Hui Ling XIANG
2
;
Chun Hong LI
4
;
Tao HAN
5
Author Information
1. The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China Department of Gastroenterology and Hepatology The Third Central Hospital of Tianjin, Tianjin 300170, China.
2. Department of Gastroenterology and Hepatology The Third Central Hospital of Tianjin, Tianjin 300170, China.
3. The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China.
4. Department of Nephrology The Third Central Hospital of Tianjin, Tianjin 300170, China.
5. Department of Gastroenterology and Hepatology The Third Central Hospital of Tianjin, Tianjin 300170, China Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin 300170, China.
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis C;
Directly acting antivirals;
Hyperuricemia;
Uric acid
- MeSH:
Antiviral Agents/therapeutic use*;
Hepatitis C, Chronic/drug therapy*;
Humans;
Hyperuricemia/drug therapy*;
Prospective Studies;
Uric Acid
- From:
Chinese Journal of Hepatology
2022;30(1):30-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the changes of serum uric acid levels and clinical characteristic in patients with chronic hepatitis C combined with hyperuricemia after direct antiviral agents (DAA) therapy. Methods: A prospective cohort study was used to investigate the risk of hyperuricemia in patients with chronic hepatitis C who received DAA treatment to obtain sustained virological response. The changes and factors influencing serum uric acid levels after 12 weeks of DAA treatment were observed. Comparisons between groups were performed using χ (2) test or Fisher's exact test, analysis of variance, Student's t test, or the non-parametric Mann-Whitney U test. Serum uric acid (SUA) changes, liver and kidney function indexes before and after treatment were compared by repeated measurement and paired t-test. Uric acid reduction was defined as a decrease in SUA from baseline at 12 weeks after treatment. Rates of change in eGFR, aspartate aminotransferase/platelet ratio, alanine aminotransferase and controlled attenuation parameter were defined from baseline (baseline to 12 weeks after treatment). Binary logistic regression analysis was used to compare the risk factors and factors influencing high and low uric acid level. Results: 161 cases with chronic hepatitis C who received DAA treatment were included, of which 19.3% patients were hyperuricemic. eGFR < 60 ml/(min·1.73 m(2)) and body mass index were independent risk factors for hyperuricemia in patients with chronic hepatitis C (eGFR: OR = 0.123, P = 0.002; body mass index: OR = 1.220, P = 0.002). SUA levels was changed significantly before treatment, at the end of treatment and at 12 weeks after treatment (327.96 vs. 320.76 vs. 314.92, F = 3.272, P = 0.042). At 12 weeks after treatment, SUA, liver stiffness, alanine aminotransferase and control attenuation parameters were all significantly lower than baseline (P < 0.05). The rate of increase in eGFR from baseline and the rate of decrease in controlled attenuation parameter during treatment were the factors influencing SUA reduction (eGFR: OR = 5124, P = 0.000; controlled attenuation index: OR = 0.010, P = 0.039). Conclusion: In chronic hepatitis C, reduced eGFR and body mass index are the risk factors for the development of hyperuricemia and a significant reduction in serum uric acid levels after DAA treatment can eradicate the virus.
